Partnership to Develop E&L Safety and Materials Database
Informatics company ACD/Labs is to combine its expertise in chemical information management with the knowledge and experience of the Extractables and Leachables Safety Information Exchange (ELSIE) consortium of bio/ pharmaceutical and medical device companies to create a searchable knowledge repository of pre-competitive data.
The new E&L database, currently in development and testing, is due to be available to member companies as an educational and research tool in Q2-2023. Accessible through an intuitive web-based interface, it aims to provide robust scientifi c search options and fl exible reporting capabilities.
“ELSIE’s guiding principle from the outset has been to have a forum to share safety data by reducing time and resources needed to gather this data, allowing our member companies to focus on developing safe and effi cacious products,” said Uma Bruen, ELSIE Chairperson. “The consortium is committed to expanding the knowledge-gathering and dissemination we currently offer through the ELSIE Safety Information Database beyond toxicological information to include extractable study results on raw materials, single-use products, drug product packaging and delivery systems and medical devices. ACD/Labs understands the science and informatics necessary to build a database that meets the needs of the E&L community. We’re excited to take
Andrew Anderson
this leap forward to improve collaboration and data sharing in this area of research.”
“Supporting scientifi c knowledge management and enabling collaborative research are two areas of focus for ACD/Labs,” said Andrew Anderson, Vice President Innovation & Informatics Strategy, ACD/Labs. “In addition to creating a resource for pre-competitive intelligence, ACD/Labs will also make available to ELSIE members the ability to manage not only their own internal toxicological and extractable data but also leachable study results on their specifi c products in a similar system, capable of interacting with the ELSIE member system. Organisations need to move away from storing data in static reports and scattered data silos to power their R&D engine with the data they generate.”
Following a recent presentation at Pittcon 2023, ELSIE
is inviting vendor and Pharma/Biopharma organisations to contribute their toxicological, physicochemical and extractables data for inclusion into the Knowledge Base.
More information online:
ilmt.co/PL/jxwp and
ilmt.co/PL/NZ6l 60247pr@reply-direct.com
Potential $50 Million Deal for Dundee Spinout
The out-licensing of both Tay Therapeutics’ BET inhibitor projects will bring potential milestone revenues of over $65 million along with tiered royalty payments of up to 10% of net annual sales.
Dr Andrew Woodland, CEO of Tay Therapeutics, said: “The second deal with VYNE is the culmination of two years of discovery and development of BET inhibitors with differentiated selectivity and safety profi les.
“I am delighted for the Tay team and consider VYNE ideally placed to continue developing and maximising the value of the BET inhibitor projects. This deal further validates Tay’s business model of growing organically using revenues to support development activities with around £6 million received in upfront and milestone payments from the VYNE collaboration to date.”
Andrew Woodland
Tay Therapeutics, a University of Dundee spinout, has agreed a licensing deal with US biotech VYNE Therapeutics focused on developing therapies for immuno-infl ammatory diseases. The agreement, potentially worth over $50 million in upfront and milestone payments, plus royalties, gives VYNE exclusive rights to develop the Scottish company’s oral BET inhibitor.
Spun out of the University’s School of Life Sciences in 2020, Tay Therapeutics currently employs 10 people at its Dundee base and focuses on Bromodomain and Extra-Terminal Domain (BET) Inhibitors. TAY-B2, now known as VYN202, (licenced in 2021) has demonstrated potent anti-infl ammatory and anti- fi brotic effects in multiple validated preclinical models. This led VYNE to exercise its option to progress the molecule for treatment of major immuno- infl ammatory conditions with high unmet need.
With the out-licence of its BET inhibitor projects, Tay Therapeutics will now focus on developing a platform to discover and develop a new class of medicine that can cause the body to ignore specifi c mutations. By restoring functional proteins, the drugs seek to address the root cause of these diseases.
David Domzalski, President and CEO of VYNE, said: “We are thrilled to be licensing the oral BET project from Tay. As a result of our productive partnership, we are poised to announce clinical results for the topical BET inhibitor that we in-licensed from Tay about two years ago and look forward to developing an oral BET inhibitor molecule in immuno-infl ammatory conditions that we believe, based on pre-clinical results, is potentially best- in-class.”
Tay is supported by its seed investors o2h Ventures, Meltwind, Wren Capital, Scottish Enterprise and the University of Dundee.
More information online:
ilmt.co/PL/063n 60324pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
